Comparison of two immunoassay systems for hCGβ and PAPP-A in prenatal screening for trisomy 21, 18 and 13 in the first trimester

Anna Elise Engell, Elin Rebecka Carlsson, Finn Stener Jørgensen, Steen Sørensen



www.elsevier.com/locate/plabm

PII: S2352-5517(17)30007-0
DOI: http://dx.doi.org/10.1016/j.plabm.2017.07.001
Reference: PLABM67

To appear in: *Practical Laboratory Medicine*

Received date: 31 January 2017
Revised date: 5 July 2017
Accepted date: 9 July 2017

Cite this article as: Anna Elise Engell, Elin Rebecka Carlsson, Finn Stene Jørgensen and Steen Sørensen, Comparison of two immunoassay systems fo hCGβ and PAPP-A in prenatal screening for trisomy 21, 18 and 13 in the firs t r i m e s t e r , *Practical Laboratory Medicine* http://dx.doi.org/10.1016/j.plabm.2017.07.001

Comparison of two immunoassay systems for hCGβ and PAPP-A in prenatal screening for trisomy 21, 18 and 13 in the first trimester

Anna Elise Engell[a*], Elin Rebecka Carlsson[a], Finn Stener Jørgensen[b], Steen Sørensen[a,c]

[a]Department of Clinical Biochemistry, Copenhagen University Hospital Hvidovre, Denmark

[b]Fetal Medicine Unit, Department of Obstetrics and Gynaecology, Copenhagen University Hospital Hvidovre, Denmark

[c]Clinical Research Centre, Copenhagen University Hospital Hvidovre, Denmark

[*]Corresponding author. annaengell@hotmail.com

Abstract

Objectives

The biochemical serum markers free β-human chorionic gonadotropin (hCGβ) and pregnancy associated plasma protein A (PAPP-A), used in screening for trisomy 21 (T21), trisomy 18 (T18), and trisomy 13 (T13) during the first trimester, can be measured on different laboratory instruments e.g. Kryptor (Brahms) and Cobas (Roche). We compared the performance of these two analytical instruments when used for first trimester combined testing.

Design and Methods

Serum samples from 944 singleton pregnant women attending for first trimester combined testing were routinely assayed for hCGβ and PAPP-A on Kryptor, and re-analyzed on Cobas. In addition, serum samples from 70 pregnant women carrying a fetus affected by T21, T18 or T13, were re-assayed on Cobas.